NETTER-2 STUDY RE LOOKING BEYONG THE HEAD
26th January 2024 The latest breakthrough in neuroendocrine cancer treatment comes from the NETTER-2 trial, where Lutetium (177Lu) oxodotreotide, a radio-labeled somatostatin analog, has shown remarkable success in treating high-grade advanced gastroenteropancreatic neuroendocrine tumours (NETs). Published at the ASCO Gastrointestinal Cancers Symposium, the results indicate a 72% reduction in the risk of progression or death, establishing a potential first-line option for patients with well-differenti - ated, high-grade tumours. While the findings are promising, real-world implementation issues like availability, accessibility, and affordability need consideration. The positive results offer hope but also raise questions about the treatment’s broader application and patients’ indi- vidual preferences and expectations. For an indepth explanation of this breakthrough and its implications for patients, please visit our website by CLICKING HERE.
RESPONSE TO NETTER-2 REPORT:
” … Results from NETTER-2 were pu combination with long-acting octreoti advanced G2 and G3 tumours. Resu (PFS) to 22.8 months in the Lutather analysis of secondary endpoints inclu Importantly this study looked at using advanced neuroendocrine neoplasm of neuroendocrine neoplasms as wel Dr Amy Eccles, Consultant Radiologi
Made with FlippingBook flipbook maker